Uterine cancer (cervix and endometrium)
Endometrium (body of the uterus): 8 432 cases · cervix: 3 159 cases (France, 2023) 1
What is it?
Uterine cancer covers two cancers. Endometrial cancer affects the lining inside the uterus. Cervical cancer affects the lower part of the uterus and is linked to human papillomavirus (HPV) in about 95 % of cases 23.
How it develops
Endometrium: hyperplasia (thickening) of the lining, especially atypical hyperplasia, may precede cancer. Cervix: persistent infection with a high-risk HPV type causes precancerous lesions, which may become cancer 23.
How long does it take to develop?
Cervix: 15 to 20 years between infection and cancer when immunity is normal 2. Endometrium: over 20 years, about 28 % of atypical hyperplasias progress to cancer 4.
Risk factors
- Endometrium: obesity, estrogen-only treatment after menopause, Lynch syndrome
- Cervix: persistent HPV infection, tobacco, weakened immunity
What helps protect you: HPV vaccination and regular cervical screening; oral contraception, pregnancies and physical activity (endometrium).
Signs that should prompt a visit to your doctor
Endometrial cancer
In the early stages
- Sometimes no symptoms
As it spreads
- Lower back or lower abdominal pain
- Swollen legs
- Urinary or digestive problems
Across several stages
Abnormal vaginal bleeding after menopause or between periods: the most common sign, which often helps it be found early
These signs do not mean you have cancer: they may have other causes. Unsure? Talk to your doctor.
⁵Cervical cancer
In the early stages (most common)
- No symptoms
- Found through screening (a sample taken from the cervix)
As it progresses
- Bleeding after sex or between periods
- Pain during sex
- Unusual discharge, sometimes with an unpleasant smell
At an advanced stage (rare)
- Lower abdominal or lower back pain
- Urinary problems
- Signs related to the organs affected
These signs do not mean you have cancer: they may have other causes. Unsure? Talk to your doctor.
⁶Endometrium: any bleeding after menopause. Cervix: bleeding after sex or between periods. Precancerous cervical lesions generally cause no signs.
Detected early or at a later stage
In the United States: 67 % of endometrial cancers are localized (bleeding often provides an early warning); 41 % of cervical cancers are localized. For the cervix, “detected early” often means finding a precancerous lesion before cancer develops 7.
5-year survival by stage
In France, 5-year net survival: endometrium 74 %, cervix 63 % 8.
Approximate correspondence with the clinical classification (TNM/FIGO); this varies depending on the tumour's characteristics.
Screening in France
Cervix: yes, from ages 25 to 65. From ages 25 to 29, cytology (a cervical smear) every 3 years after 2 initial normal tests 1 year apart; from ages 30 to 65, an HPV test every 5 years. Endometrium: no organized cancer screening 9.
Monitoring for people at risk
HPV vaccination is recommended from ages 11 to 14, with catch-up vaccination up to age 26 for girls and boys. Specific follow-up for people with Lynch syndrome 10.

Prevonco is currently available in France only.
An aid to the early detection of 16 cancers
No prescription needed, for people without symptoms. If you have an unexplained symptom, see your doctor first.
Pre-register for free →Frequently asked questions
Do I need a prescription?
No. With Prevonco, you do not need a prescription: after ordering online, a unique code gives you access to the test at one of our partner laboratories. In France, some laboratory tests can be carried out at your request, without a prescription.
No prescription, but still a doctor: they remain central to the process. Your result is sent to the doctor you selected from our panel, who will explain it during a 30-minute video consultation, included whatever the result.
Are you receiving care for cancer? Speak directly to your oncologist: they can prescribe this test without going through Prevonco.
For any questions about your situation, or if you have symptoms, your doctor remains your first point of contact.
What if my level is high?
A high level tends to be a strong signal. It is not a conclusion: its cause needs to be investigated with a doctor.¹¹
Your result is sent to the doctor you selected from our panel. They will explain it during the 30-minute video consultation included in the price. Further investigations prescribed by a doctor can help identify the cause.¹¹
What if the level is intermediate? It may not be related to cancer (smoking, an inflammatory condition, etc.). Other blood tests may be suggested; if they are normal, a repeat check is planned at 12 months. You will never be left to face your result alone.¹¹
What if my level is low?
That is reassuring, but no test is perfect: a low level does not rule everything out.¹¹
If you have no symptoms, no specific follow-up is recommended after a low result. The risk of a false negative varies by cancer type.¹¹
Your doctor, who is trained in functional medicine and specialises in prevention, will help you explore any concerns or symptoms during the 30-minute video consultation.¹¹
Keep up with your usual screening: respond to invitations for organised screening programmes, and see your doctor if a symptom appears.¹¹
How long will it take to get my results?
The laboratory analysis takes 30 days. Your full results are presented by a doctor trained in functional medicine during a 30-minute consultation included in your package.
You choose the date and time slot that suit you for this appointment.
Prevonco is currently available in France only.
An aid to the early detection of 16 cancers
No prescription needed, for people without symptoms. If you have an unexplained symptom, see your doctor first.
Pre-register for free →General information for educational purposes: it does not replace your doctor's advice. An aid to early detection: it does not replace organised screening, imaging tests or your doctor's advice.
Sources
- 1.INCa, Panorama des cancers en France, 2026
- 2.OMS, fiche d’information sur le cancer du col de l’utérus, 2026
- 3.American Cancer Society, Endometrial Cancer Risk Factors
- 4.Lacey et al., Journal of Clinical Oncology, 2010 (HealthDay summary)
- 5.INCa (cancer.fr, 31/05/2022); Fondation ARC, 2026
- 6.INCa (cancer.fr, 07/10/2026; tool for doctors 2021); Assurance Maladie
- 7.NCI SEER, Cancer Stat Facts – Uterine Cancer, Cervical Cancer (2016-2022)
- 8.Santé publique France, survie des personnes atteintes de cancer 1989-2018
- 9.Santé.fr, cancer du col de l’utérus : vos questions sur le dépistage
- 10.Vidal, Gardasil 9 remboursé jusqu’à 26 ans, 2025
- 11.biodena.care